Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer

Gynecologic Oncology

Volumn 93, Issue 1, 2004, Pages 223-228

  Prasad, Monica ^a   Ben Porat, Leah ^a   Hoppe, Brad ^a   Aghajanian, Carol ^a   Sabbatini, Paul ^a   Chi, Dennis S ^a   Hensley, Martee L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gemcitabine; Ovarian cancer; Second line therapy; Topotecan

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER RECURRENCE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RECURRENT DISEASE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; DEOXYCYTIDINE; DRUG COSTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; SALVAGE THERAPY; TOPOTECAN;

EID: 1842582410     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.01.014     Document Type: Article

References (18)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., Thun M.J. Cancer statistics, 2003. CA Cancer J. Clin. 53(1):2003;5-26.
2. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y.et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1):1996;1-6.
3. Lund B., Hansen O.P., Neijt J.P., Theilade K., Hansen M. Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs. 6(Suppl. 6):1995;61-62.
4. Friedlander M., Millward M.J., Bell D., Bugat R., Harnett P., Moreno J.A.et al. A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oncol. 9(12):1998;1343-1345.
5. Creemers G.J., Bolis G., Gore M., Scarfone G., Lacave A.J., Guastalla J.P.et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J. Clin. Oncol. 14(12):1996;3056-3061.
6. Swisher E.M., Mutch D.G., Rader J.S., Elbendary A., Herzog T.J. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol. Oncol. 66(3):1997;480-486.
7. Kudelka A.P., Tresukosol D., Edwards C.L., Freedman R.S., Levenback C., Chantarawiroj P.et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. 14(5):1996;1552-1557.
8. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B. et al. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J. Clin. Oncol. 16(10):1998;3345-3352.
9. ten Bokkel Huinink W., Gore M., Carmichael J., Gordon A., Malfetano J., Hudson I.et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J. Clin. Oncol. 15(6):1997;2183-2193.
10. Gore M., ten Bokkel Huinink W., Carmichael J., Gordon A., Davidson N., Coleman R.et al. Clinical evidence for topotecan-paclitaxel non-cross- resistance in ovarian cancer. J. Clin. Oncol. 19(7):2001;1893-1900.
11. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S.et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9(3):1991;389-393.
12. Rustin G.J., Nelstrop A.E., McClean P., Brady M.F., McGuire W.P., Hoskins W.J.et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J. Clin. Oncol. 14(5):1996;1545-1551.
13. Hensley M.L., Hoppe B., Leon L., Sabbatini P., Aghajanian C., Chi D.et al. The costs and efficacy of liposomal doxorubicin in platinum-refractory ovarian cancer in heavily pretreated patients. Gynecol. Oncol. 82(3):2001;464-469.
14. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., Belinson J. Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Gynecol. Oncol. 79(1):2000;116-119.
15. Gronlund B., Hansen H.H., Hogdall C., Engelholm S.A. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma. Cancer. 95(8):2002;1656-1662.
16. Morris R.T. Weekly topotecan in the management of ovarian cancer. Gynecol. Oncol. 90(3 Pt 2):2003;S34-S38.
17. Hoskins P., Eisenhauer E., Beare S., Roy M., Drouin P., Stuart G.et al. Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. J. Clin. Oncol. 16(6):1998;2233-2237.
18. Silver D.F., Piver M.S. Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum. Am. J. Clin. Oncol. 22(5):1999;450-452.